Login / Signup

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

Richard E PratleyRoy EldorAnnaswamy RajiGregory GolmSusan B HuyckYanping QiuSheila SungaJeremy JohnsonSteven G TerraJames P MancusoSamuel S EngelBrett Lauring
Published in: Diabetes, obesity & metabolism (2018)
In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents.
Keyphrases
  • type diabetes
  • gestational age
  • glycemic control
  • cardiovascular disease
  • insulin resistance
  • metabolic syndrome